{"protocolSection": {"identificationModule": {"nctId": "NCT02059512", "orgStudyIdInfo": {"id": "NBK-2901-AMNKM"}, "organization": {"fullName": "St. Petersburg State Pavlov Medical University", "class": "OTHER"}, "briefTitle": "Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease", "officialTitle": "Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease", "acronym": "TAMIS"}, "statusModule": {"statusVerifiedDate": "2021-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-01", "studyFirstSubmitQcDate": "2014-02-10", "studyFirstPostDateStruct": {"date": "2014-02-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-03-27", "resultsFirstSubmitQcDate": "2021-05-20", "resultsFirstPostDateStruct": {"date": "2021-05-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-05-20", "lastUpdatePostDateStruct": {"date": "2021-05-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "St. Petersburg State Pavlov Medical University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study evaluate the effect of the method of administration of autologous bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts in the surgical treatment of coronary heart disease, to assess the degree of effectiveness depending on the method of transplantation (intramyocardial, intracoronary, combined).", "detailedDescription": "Additional estimation of safety:\n\n1. Assessment of EuroScore II.\n2. Hospital Stay.\n3. The duration of stay in the intensive care unit.\n4. Restoration of cardiac rhythm at the end of the main stage of operation (defibrillation/ self-recovery).\n5. The time of extracorporeal circulation.\n6. Time of anoxia.\n7. Volume abjointed (drainage) postoperative day 1, day 3\n8. Troponin I, CPK-MB, Myoglobin at 1, 3 postoperative days.\n9. Hb/ HCT/K+ at the end of cardiopulmonary bypass (CPB) and Hb/ HCT/K+/ ABC at the end of the operation.\n10. Assessment of the degree of manifestation of a systemic inflammatory reaction in the postoperative period - leukocytes (Leu), CRP\n11. Postoperative complications (hydrothorax, hydropericardium, arrhythmias, resternotomy).\n12. Echocardiography at 7-14 days after surgery.\n\nEstimation of efficiency:\n\n1. Evaluation of systolic and diastolic myocardial function. Assessment of myocardial perfusion and metabolism (before and after treatment) - Speckle tracking echocardiography.\n2. Patency of grafts within a specified time of treatment (angiography).\n3. Dependence and duration of positive clinical effect on the amount of injected cell material.\n4. Evaluation of the quality of life (Minnesota questionnaire, Seattle questionnaire, SF- 36 questionnaire).\n5. All-cause Mortality Associated With the Progression of Basic\n6. Disease.Dynamics of the functional class of angina.\n7. Dynamics of the functional class of heart failure.\n8. Dynamics of test data with a 6-minute walk.\n\nPredicting the results of treatment (the effect of a number of parameters):\n\n1. Age.\n2. Gender.\n3. The body mass index.\n4. Diabetes.\n5. Smoking.\n6. Family history of cardiovascular events.\n7. Duration of ischemic heart disease.\n8. Serum total cholesterol (+ fractions).\n9. Leukocytosis and CRP level (initial level and rate of decrease in the postoperative period).\n10. The level of creatinine.\n11. The presence / absence of extracardiac arteriopathy.\n12. The intramyocardial or intracoronary injection of BM-MNCs.\n13. Assessment of the bone marrow: the number of nucleated cells, CD34 +, CD133 +."}, "conditionsModule": {"conditions": ["Ischemic Heart Disease", "Bone Marrow Cells", "Coronary Artery Bypass Grafting (CABG)", "Heart Failure, Diastolic"], "keywords": ["ischemic heart disease", "bone marrow cells", "coronary artery bypass grafting (CABG)", "reperfusion injury", "myocardial dysfunction, diastolic", "Heart Failure, Diastolic", "transplantation of autologous mononuclear cells", "intramyocardial administration", "intracoronary administration"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Potential participants in this study were all patients admitted for planned coronary artery bypass grafting under extracorporeal circulation and who, according to angiographic examination, had 3 or more stenotic coronary arteries. The final decision on the inclusion of each individual patient in this study was determined taking into account the inclusion criteria. The study was conducted according to the approved protocol as a randomized, blind, placebo controlled.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "Randomization into three observation groups was carried out according to the table of random numbers.", "whoMasked": ["INVESTIGATOR"]}}, "enrollmentInfo": {"count": 117, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group 1", "type": "ACTIVE_COMPARATOR", "description": "Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.", "interventionNames": ["Procedure: Group 1"]}, {"label": "Group 0", "type": "PLACEBO_COMPARATOR", "description": "Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.", "interventionNames": ["Procedure: Group 0"]}, {"label": "Group 2", "type": "ACTIVE_COMPARATOR", "description": "Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.", "interventionNames": ["Procedure: Group 2"]}], "interventions": [{"type": "PROCEDURE", "name": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.", "armGroupLabels": ["Group 1"], "otherNames": ["CABG with intramyocardial administration of ABMMC."]}, {"type": "PROCEDURE", "name": "Group 0", "description": "Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.", "armGroupLabels": ["Group 0"], "otherNames": ["CABG with administration of 0.9 % sodium chlorid."]}, {"type": "PROCEDURE", "name": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.", "armGroupLabels": ["Group 2"], "otherNames": ["CABG with intramyocardial and intracoronary administration of ABMMC."]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Assessment of the Initial Risk of Surgery (EuroScore II).", "description": "EuroScoreII is intended to assess the risk of adverse outcome of coronary artery bypass grafting. Assessment factors: age, sex, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, IV class of angina severity, active endocarditis, unstable angina, surgery, critical condition of the patient before surgery, type of surgery. The higher the percentage, the higher the risk of surgery.", "timeFrame": "Before CABG surgery at baseline."}, {"measure": "Length of Hospital Stay. Length of Stay in the Intensive Care Unit.", "description": "The results were obtained from the analysis of primary data.", "timeFrame": "Primary hospitalization for planned CABG."}, {"measure": "The Severity of the Systemic Inflammatory Response in the Postoperative Period (Leukocytosis).", "description": "Assessment of the severity of the systemic inflammatory response during hospital stay after surgery. Assessment of the level of inflammation by the severity of an increase in leukocytes (leukocytosis).\n\nLeukocytosis - an increase in the number of leukocytes per unit volume of blood. The norm of leukocytes in the blood is 5.5-8.810\\^9 /l. For adults, leukocytosis is considered to be an increase in the number of leukocytes in the blood of more than 9.0\\*10\\^9 / l In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.", "timeFrame": "The parameters were evaluated initially at baseline in the postoperative period - an interval of 0-6 hours, 12-18 hours, 18-24 hours, 48 hours, 72 hours, 96 hours, 7 days and 14 days."}, {"measure": "Assessment of the Degree of General Inflammatory Response (C-reactive Protein (CRP)),", "description": "Results of dynamic control of laboratory parameters of CRP. C-reactive protein. This fraction of plasma proteins increases in the presence of an inflammatory process in the body. It is synthesized in response to the ingestion of toxins of pathological microorganisms into the bloodstream and neutralizes them by binding them. In addition, it appears when the body's own cells are destroyed in the event of necrosis, tumor disintegration or extensive trauma, inactivating the resulting products. In addition to eliminating toxins, CRP triggers a cascade of immune responses aimed at eliminating pathologically altered structures.\n\nNormally absent (or less than 0.4 mg / l). In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.", "timeFrame": "Initial data, control point in the interval 4-6 days of the postoperative period, control point in the interval 12-14 days of the postoperative period."}, {"measure": "The Volume of Discharge Through the Drains in the Early Postoperative Period.", "description": "A daily assessment of the discharge by drainage before removal was carried out. It was carried out to assess the possible development of an excessive inflammatory reaction (polyserositis phenomena) in response to the transplantation of autologous bone marrow mononuclear cells.", "timeFrame": "Evaluation of these data - for the time spent in the intensive care unit before removing the drains."}, {"measure": "Dynamics of Markers of Myocardial Damage (Troponin I, Myoglobin).", "description": "Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.", "timeFrame": "1 and 3 days of the postoperative period."}, {"measure": "Dynamics of Markers of Myocardial Damage (Creatine Phosphokinase Fraction MB (CPK-MB)).", "description": "Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.", "timeFrame": "1 and 3 days of the postoperative period."}, {"measure": "Intraoperative Assessment of Homeostasis (Hemoglobin (Hb).", "description": "These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.", "timeFrame": "Intraoperative data."}, {"measure": "Intraoperative Assessment of Homeostasis (Hematocrit (HCT)).", "description": "These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.", "timeFrame": "Intraoperative data."}, {"measure": "Intraoperative Assessment of Homeostasis (\u041a+).", "description": "These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.", "timeFrame": "Intraoperative data."}, {"measure": "Cardiopulmonary Bypass Time.", "timeFrame": "Intraoperative data."}, {"measure": "Time of Aortic Clamping (Anoxia).", "description": "Estimation of the time from the moment the clamp is applied to the aorta (complete clamping of the aorta) to the removal of the clamp from the aorta.", "timeFrame": "Intraoperative data."}, {"measure": "Assessment of Complications in the Postoperative Period. Additional Estimation of Safety.", "description": "The presence of complications in the postoperative period (Hydrothorax, Hydropericardium, Cardiac arrhythmias - atrial fibrillation / atrial flutter).", "timeFrame": "Postoperative period."}, {"measure": "Left Ventricular Ejection Fraction - Echocardiography - Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular the left ventricular ejection fraction, was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The lower the indicator, the worse the prognosis of an unfavorable outcome.", "timeFrame": "7-14 days of the postoperative period"}, {"measure": "Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment - Echocardiography (Size of the Left Ventricle - Index). Additional Estimation of Safety.", "description": "Assessment of myocardial contractility according to echocardiography, in particular the size of the left ventricle - its index, was carried out within 7-14 days of the postoperative period, depending on the clinical condition of the patient, as well as on the maximum information content of this study. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.\n\nThe index is used as an indicator of payment to obtain a more reliable result (taking into account the individual characteristics of each patient).\n\nindex - left ventricular size (mm.)/ body mass index (kg/m\\^2).", "timeFrame": "7-14 days after surgery"}, {"measure": "Volume of the Left Ventricle - Index - Echocardiography. Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular volume of the left ventricle - index was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The greater the figure (volume of the left ventricle - index), the worse the prognosis of adverse outcome.\n\nThe index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - volume of the left ventricle (ml.)/ body mass index (kg / m\\^2).", "timeFrame": "7-14 days after surgery"}, {"measure": "Restoration of the Heart Rate After the Completion of the Main Stage of the Surgical Intervention. Additional Estimation of Safety.", "description": "The need to perform defibrillation to restore sinus rhythm, at the end of the main stage of surgery.", "timeFrame": "Upon completion of the main stage of surgery."}], "secondaryOutcomes": [{"measure": "All-cause Mortality Associated With the Progression of Basic Disease.", "description": "The total number of deaths - in the primary hospitalization and during the observation period of 12 months after surgical treatment - deaths associated with the progression of the initial disease.\n\nThe complication rate for CABG operations is 30\u00b110%. According to n1=kn2; n1 sample size, in the control. In group 0, k=2/3 times more than in group 1 and group 2. The difference between the test and control frequencies is \u03b5=p1-p2. Accordingly, with p1 = 0.2; p2=0.4, \u03b4= 0.1; n1=49.5, n2=33. The result is group 0 - 36, group 1 and 2 - 25+25 = 50. The null hypothesis of complication rate \u03b4.All patients included in the study.", "timeFrame": "12 months after surgery"}, {"measure": "Quality of Life. Evaluation of the Quality of Life (Minnesota Questionnaire (MHFLQ), Seattle Questionnaire (SAQ), SF-36 Questionnaire). Estimation of Efficiency.", "description": "The SF-36 questionnaire. The indicators of each scale vary between 0 and 100, where 100 represents total health. The results are presented in the form of scores on 8 scales, compiled in such a way that a higher score indicates a higher level of quality of life.MHFLQ - for patients with heart failure.The specified questionnaire consists of 21 questions. To answer each question, a scale of 6 points from the minimum intensity of certain symptoms to the maximum is used. The assessment is based on the sum of points, where the maximum number of points - 105 corresponds to the patient's worst condition. The lowest score 0 points is the best clinical condition of the patient. SAQ consists of 19 questions about the patient's condition, which are divided into the following 5 scales. The quality of life for each of the five scales under consideration is measured in percent, with 0% corresponding to the worst quality of life, and 100% to the best.", "timeFrame": "At baseline and after one year."}, {"measure": "Assessment of the Functional Class of Exertional Angina at 12 Months After Surgical Treatment.", "description": "1. functional class - The usual load does not cause changes in the state of health. Painful attacks occur against the background of excessive loads - after climbing several flights of stairs, while walking fast.\n2. functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.\n3. functional class - The patient does not tolerate minimal physical activity. An attack occurs when walking a distance of 50-100 meters. Climbing stairs is difficult.\n4. functional class - Activity is significantly limited. Angina pectoris manifests itself when performing minimal actions, including at rest.", "timeFrame": "up to 12 months"}, {"measure": "Dynamics of the Functional Class of Heart Failure (NYHA). Estimation of Efficiency.", "description": "1. functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.\n2. functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.\n3. functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.\n\nThe smaller the functional class, the better the quality of human life.", "timeFrame": "Assessment of the dynamics at 12 months after treatment."}, {"measure": "Evaluation of the Left Ventricular Ejection Fraction 12 Months After Treatment.", "description": "According to echocardiography.", "timeFrame": "12 months after treatment."}, {"measure": "Estimation of the Index of Linear Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular the size of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.\n\nThe index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - size of the left ventricle (mm.)/ body mass index (kg/m\\^2).", "timeFrame": "12 months after the treatment."}, {"measure": "Estimation of the Index of Volumetric Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular the volume of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular volume - index), the worse the prognosis of an unfavorable outcome.\n\nThe index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - volume of the left ventricle (mm.)/ body mass index (kg/m\\^2).", "timeFrame": "12 Months After the Treatment"}, {"measure": "Assessment of Left Ventricular Diastolic Function - Peak E of Transmitral Flow and Peak \u0410 of Transmitral Flow 12 Months After Treatment.", "description": "Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.", "timeFrame": "12 months after treatment."}, {"measure": "Assessment of Left Ventricular Diastolic Function E/A - 12 Months After Treatment.", "description": "The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.", "timeFrame": "12 months after treatment"}, {"measure": "Assessment of Left Ventricular Diastolic Function - DT and IVRT 12 Months After Treatment.", "description": "Echocardiographic data ( DT (Half-time of wave E), time of isovolumic relaxation of the left ventricle (IVRT).\n\nDT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; \\> 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; \\<150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) \\<100 ms - normal; \\> 100 ms - violation of relaxation", "timeFrame": "12 Months After Treatment."}, {"measure": "Distance Traveled in the 6-minute Walk Test. Test Results With 6 Minute Walk", "description": "The dynamic of the number of meters walked according to the 6-minutes walk test (6MWD) in the observation groups.", "timeFrame": "initially and after 12 months"}, {"measure": "The Number of Functioning Grafts 12 Months After CABG. Patency of Grafts Within a Specified Time of Treatment (Angiography).", "description": "According to the angiographic study.", "timeFrame": "up to 12 months"}, {"measure": "Analysis of the Effect of Left Ventricular Diastolic Dysfunction on the Patency of the Grafts.", "description": "Echocardiographic data.", "timeFrame": "up to 12 months"}], "otherOutcomes": [{"measure": "The Volume of Cellular Material (Cytosis).", "description": "Dependence and Duration of Positive Clinical Effect on the Amount of Injected Cell Material (cytosis).", "timeFrame": "Initial data at the time of collection of bone marrow cells."}, {"measure": "The Amount of Cell Material (Percentage).", "description": "Dependence and duration of positive clinical effect on the amount of injected cell material (Mononuclear fraction %, CD34+ %, CD133+ %).\n\nAssessment - mononuclear fraction, CD 34 +, CD 133+ according to flow cytometry data.", "timeFrame": "Initial data at the time of collection of bone marrow cells."}, {"measure": "Smoking as a Factor That Negatively Affects the Results of the Test With a 6-minute Walk in Dynamics.", "description": "The distance covered (in meters) was compared with the proper value depending on age (years), height (cm), weight (kg), body mass index (BMI). The due values (6MWD (i)) were calculated using the following formulas: For men: 6\u041cWD (i) = 7.57 \u00d7 height - 5.02 \u00d7 age - 1.76 \u00d7 weight - 309 or 6MWD (i) = 1140 - 5.61 \u00d7 BMI - 6.94 \u00d7 age. For women:\n\n6\u041cWD (i) = 2.11 \u00d7 height - 2.29 \u00d7 weight - 5.78 \u00d7 age + 667 Or 6\u041cWD (i) = 1017 - 6.24 \u00d7 BMI - 5.83 \u00d7 age. This difference at baseline is reported as distance walked for smokers minus non-smokers.", "timeFrame": "12 months after treatment."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women from 18 to 80 years\n* Patients with angina pectoris III-IV functional class\n* According to angiographic examination, the presence of 3 or more stenotic coronary arteries\n* Aorto-coronary bypass surgery under cardiopulmonary bypass\n* Patients signed informed consent\n\nExclusion Criteria:\n\n* Intolerance of heparin and HES.\n* Hypothyroidism and hyperthyroidism.\n* Associated pathology with a projected lifespan limitation to 3 years.\n* infection diseases\n* Simultaneous participation in another study.\n* Pregnancy.\n* Severe mental disorder.\n* Refusal of a patient to participate in the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Vladimir V Komok, Ph.D", "affiliation": "First Pavlov State Medical University of St. Petersburg.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "First Pavlov State Medical University of St. Petersburg", "city": "St. Petersburg", "zip": "197089", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}]}, "referencesModule": {"references": [{"type": "BACKGROUND", "citation": "Komok V.V., Bunenkov N.S., Beliy S.A., Pizin V.M., Kondratev V.M., Dulaev \u0410.V., Lukashenko V.I., Kobak A.E., Maksimova T.S., Sergienko I.P., Parusova E.V., Smirnova L.A., Babenko E.V., Afanasev B.V., Nemkov A.S., Khubulava G.G. Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS). Russian Journal of Transplantology and Artificial Organs. 2019;21(2):112-120. (In Russ.) https://doi.org/10.15825/1995-1191-2019-2-112-120"}, {"type": "BACKGROUND", "citation": "Komok V.V., Bunenkov N.S., Beliy S.A., Pizin V.M., Kondratev V.M., Dulaev A.V., Kobak A.E., Maksimova T.S., Sergienko I.P., Parusova E.V., Smirnova L.A., Babenko E.V., Afanasev B.V., Nemkov A.S., Khubulava G.G. Evaluation of the effectiveness of combined treatment of coronary heart disease - coronary artery bypass grafting, transplantation of autologous bone marrow mononuclear cells: a randomized, double-blind, placebo-controlled study. Russian Journal of Transplantology and Artificial Organs. 2019;21(4):54-66. https://doi.org/10.15825/1995-1191-2019-4-54-66"}], "seeAlsoLinks": [{"label": "Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS).", "url": "https://journal.transpl.ru/vtio/article/view/1027"}, {"label": "Evaluation of the effectiveness of combined treatment of coronary heart disease - coronary artery bypass grafting, transplantation of autologous bone marrow mononuclear cells: a randomized, double-blind, placebo-controlled study.", "url": "https://journal.transpl.ru/vtio/article/view/1106"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study included patients admitted for routine coronary artery bypass grafting under cardiopulmonary bypass, and having, according to the angiographic studies, 3 or more of stenosed coronary arteries. Patients met the inclusion criteria and signed an informed voluntary consent.", "recruitmentDetails": "Potential participants in the study were all patients referred to the clinic for surgical treatment of coronary artery disease.", "groups": [{"id": "FG000", "title": "Intramyocardial Administration 0.9 % NaCl (Sodium Chloride) - Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "FG001", "title": "Intramyocardial Administration Autologous Bone Marrow Stem Cells - Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "FG002", "title": "Intramyocardial and Intracoronary Administration Autologous Bone Marrow Stem Cells - Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}, {"groupId": "FG001", "numSubjects": "34"}, {"groupId": "FG002", "numSubjects": "37"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "37"}, {"groupId": "FG001", "numSubjects": "25"}, {"groupId": "FG002", "numSubjects": "23"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "14"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The study included patients admitted for coronary artery bypass grafting. Patients met the inclusion criteria and signed an informed consent.\n\nIn the \"results\" section, data are provided for repeated examinations of patients.", "groups": [{"id": "BG000", "title": "Intramyocardial Administration 0.9 % NaCl (Sodium Chloride) - Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "BG001", "title": "Intramyocardial Administration Autologous Bone Marrow Stem Cells - Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "BG002", "title": "Intramyocardial and Intracoronary Administration Autologous Bone Marrow Stem Cells - Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial ( 0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow mononuclear cells."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "85"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "67"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "18"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61", "spread": "8"}, {"groupId": "BG001", "value": "61.7", "spread": "6.8"}, {"groupId": "BG002", "value": "59.5", "spread": "5.4"}, {"groupId": "BG003", "value": "60.9", "spread": "6.96"}]}]}]}, {"title": "Sex: Female, Male", "description": "Gender sign: Female, Male", "populationDescription": "The analysis of the final statistics was made at the time the studies were completed.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "13"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "72"}]}]}]}, {"title": "Region of Enrollment", "description": "North-West Russia:Novgorod region, Leningrad region, Pskov region.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Russia", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "85"}]}]}]}, {"title": "BMI", "description": "BMI (body mass index) = weit (kg)/(height (m))\\^2 Norm (18.5-25); 1-overweight (25-30); I degree of obesity (30-35); II degree of obesity (35-40); III degree of obesity (40 and\\>).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.6", "spread": "3.59"}, {"groupId": "BG001", "value": "28.05", "spread": "4.46"}, {"groupId": "BG002", "value": "28.09", "spread": "3.57"}, {"groupId": "BG003", "value": "28.3", "spread": "3.4"}]}]}]}, {"title": "Diabetes", "description": "According to laboratory data - compensated (diet, drug therapy, insulin).", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "15"}]}]}]}, {"title": "Hypertonic desease (stage).", "description": "2 stage - Blood pressure ranges from 160/100 to 179/109 mm Hg. There are signs of damage to the heart, retina and kidneys, which can only be detected by instrumental or laboratory examination methods. There are no subjective symptoms of their defeat.\n\n3 stage - Blood pressure is 180/110 mm Hg. and higher. There are objective signs and subjective symptoms of the heart, the brain, retina, kidney, or blood vessels.\n\nStage 2 is associated with a lower risk of adverse cardiovascular events.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "2 stage", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "3 stage", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "84"}]}]}]}, {"title": "Arterial hypertension (degree)", "description": "1. degree - Blood pressure ranges from 140/90 to 159/99 mm. Hg\n2. degree - Blood pressure ranges from 160/100 to 179/109 mm Hg.\n3. degree - Blood pressure is 180/110 mm Hg. and higher.\n\nDegree 1 and 2 is associated with a lower risk of adverse cardiovascular events.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "7"}]}]}, {"title": "1 degree", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "16"}]}]}, {"title": "2 degree", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "32"}]}]}, {"title": "3 degree", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "30"}]}]}]}, {"title": "Peripheral arteriopathy.", "description": "The presence of peripheral arteriopathy (hemodynamically significant stenosis in the carotid arteries, arteries of the lower extremities).\n\nAccording to ultrasound, angiographic research methods: carotid arteries, lower limb arteries.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "21"}]}]}]}, {"title": "Acute myocardial infarction transferred in history (number).", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "1 acute myocardial infarctions", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "40"}]}]}, {"title": "2 acute myocardial infarctions", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "13"}]}]}, {"title": "3 acute myocardial infarctions", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}]}]}, {"title": "Smoking.", "description": "Active smoking at the time of hospitalization for routine CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "13"}]}]}]}, {"title": "Family history of cardiovascular disease.", "description": "Family history of cardiovascular disease: hypertension, arterial hypertension, AMI, stroke, the presence of peripheral arteriopathy requiring medical intervention.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "40"}]}]}]}, {"title": "Debut of ischemic heart disease (months).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.9", "spread": "70.9"}, {"groupId": "BG001", "value": "62.9", "spread": "79.2"}, {"groupId": "BG002", "value": "76.9", "spread": "59.4"}, {"groupId": "BG003", "value": "69.3", "spread": "60.3"}]}]}]}, {"title": "Debut of ischemic heart disease.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Debut of ischemic heart disease up to 5 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "51"}]}]}, {"title": "Debut of ischemic heart disease 6-10 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "20"}]}]}, {"title": "Debut of ischemic heart disease over 10 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "14"}]}]}]}, {"title": "Angina pectoris (functional class).", "description": "2 functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.\n\n3 functional class. Attacks when walking on level ground at 100-500 meters, when climbing stairs one floor.\n\n4 functional class. Seizures when walking on level ground at a distance of less than 100 meters, and when at rest.\n\nPainless myocardial ischemia is characterized by changes in myocardial blood supply without pain.\n\nThe lower the functional class of angina pectoris, the better the quality of life.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "2 functional class", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "3 functional class", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "76"}]}, {"title": "4 functional class", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}]}, {"title": "painless ischemia", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}]}, {"title": "Heart failure (functional class NYHA).", "description": "1. functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.\n2. functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.\n3. functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.\n\nThe smaller the functional class, the better the quality of human life.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "1 functional class", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}, {"title": "2 functional class", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "74"}]}, {"title": "3 functional class", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Total holesterol (mmol/l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.49", "spread": "1.08"}, {"groupId": "BG001", "value": "4.5", "spread": "1.24"}, {"groupId": "BG002", "value": "4.6", "spread": "1.49"}, {"groupId": "BG003", "value": "4.5", "spread": "1.1"}]}]}]}, {"title": "Very loud density lipoprotein (mmol/l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.96", "spread": "0.35"}, {"groupId": "BG001", "value": "0.94", "spread": "0.5"}, {"groupId": "BG002", "value": "0.77", "spread": "0.3"}, {"groupId": "BG003", "value": "0.95", "spread": "0.31"}]}]}]}, {"title": "High density lipoproteins (mmol/l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.7", "spread": "0.89"}, {"groupId": "BG001", "value": "2.58", "spread": "1.05"}, {"groupId": "BG002", "value": "2.7", "spread": "1.26"}, {"groupId": "BG003", "value": "2.6", "spread": "1.1"}]}]}]}, {"title": "Loud density lipoproteins (mmol/l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.98", "spread": "0.31"}, {"groupId": "BG001", "value": "1.16", "spread": "0.37"}, {"groupId": "BG002", "value": "1.13", "spread": "0.29"}, {"groupId": "BG003", "value": "1.1", "spread": "0.3"}]}]}]}, {"title": "Triglyceride (mmol/l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.04", "spread": "0.68"}, {"groupId": "BG001", "value": "1.69", "spread": "0.72"}, {"groupId": "BG002", "value": "1.63", "spread": "0.62"}, {"groupId": "BG003", "value": "1.9", "spread": "0.65"}]}]}]}, {"title": "Atherogenic coefficient.", "description": "The data at the time of hospitalization for routine CABG. Atherogenic Coefficient (AC) is a predictor of the risk of coronary artery disease and is calculated as {(Total Cholesterol - HDLc)/HDLc}.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.07", "spread": "1.32"}, {"groupId": "BG001", "value": "3.27", "spread": "1.9"}, {"groupId": "BG002", "value": "4.5", "spread": "5.2"}, {"groupId": "BG003", "value": "4.08", "spread": "2.1"}]}]}]}, {"title": "Creatinine (mmol / l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.09", "spread": "0.02"}, {"groupId": "BG001", "value": "0.09", "spread": "0.02"}, {"groupId": "BG002", "value": "0.08", "spread": "0.02"}, {"groupId": "BG003", "value": "0.09", "spread": "0.02"}]}]}]}, {"title": "C-reactive protein (mg/l).", "description": "The data at the time of hospitalization for routine CABG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/l", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.9", "spread": "11.07"}, {"groupId": "BG001", "value": "2.56", "spread": "1.96"}, {"groupId": "BG002", "value": "5.3", "spread": "5.38"}, {"groupId": "BG003", "value": "4.9", "spread": "6.8"}]}]}]}, {"title": "Glomerular filtration rate (ml/min/1.73 m^2) (assessment of renal function).", "description": "The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Formula):scale was used to assess renal function. The degree of renal dysfunction was assessed according to https://www.kidney.org/professionals/explore-your-knowledge/how-to-classify-ckd The standards are as follows: Category G1 \u226590 ml/min/1.73 m\\^2 (Normal or high); G2 - 60-89 ml/min/1.73 m\\^2 (Mildly decreased); G3a - 45-59 ml/min/1.73 m\\^2 (Mildly to moderately decreased); G3b - 30-44 ml/min/1.73 m\\^2 (Moderately to severely decreased); G4 15-29 ml/min/1.73 m\\^2 (Severely decreased); G 5 \\<15 ml/min/1.73 m\\^2 (Kidney failure).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/min/1.73 m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.89", "spread": "15.8"}, {"groupId": "BG001", "value": "77.6", "spread": "16.03"}, {"groupId": "BG002", "value": "84.2", "spread": "17.26"}, {"groupId": "BG003", "value": "77.9", "spread": "16.8"}]}]}]}, {"title": "EuroScore II", "description": "EuroScoreII is designed to assess the risk of adverse outcome in coronary artery bypass grafting. Assessment factors: age, gender, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, grade IV angina pectoris, active endocarditis, unstable angina pectoris, surgery, critical condition of the patient before surgery, type of surgery. The higher the score, the higher the risk of an adverse outcome.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of risk", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.3", "spread": "0.68"}, {"groupId": "BG001", "value": "1.07", "spread": "0.47"}, {"groupId": "BG002", "value": "1.02", "spread": "0.4"}, {"groupId": "BG003", "value": "1.15", "spread": "0.5"}]}]}]}, {"title": "SYNTAX Score", "description": "The SYNTAX Score Calculator is a scale developed in connection with the SYNTAX study The scale includes an assessment of the nature of the anatomical structure and atherosclerotic lesions of the coronary arteries. Each factor has a certain score. Based on the summation of the scores, the risk stratification is assessed. The following risk groups have been identified. Low-risk group with a score of 0-22, medium-risk group 23-32 points, high-risk group\\> 32 points. http://www.syntaxscore.com/calculator/syntaxscore/frameset.htm", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.7", "spread": "7.0"}, {"groupId": "BG001", "value": "26.8", "spread": "6.0"}, {"groupId": "BG002", "value": "26.4", "spread": "7.3"}, {"groupId": "BG003", "value": "26.7", "spread": "6.4"}]}]}]}, {"title": "Nitrates.", "description": "Number participants who were receiving Nitrates treatment. Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "42"}]}]}]}, {"title": "Diuretics.", "description": "Number participants who were receiving Diuretics treatment. Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "18"}]}]}]}, {"title": "Angiotensin converting enzyme inhibitors.", "description": "Number participants who were receiving Angiotensin converting enzyme inhibitors treatment. Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "43"}]}]}]}, {"title": "Angiotensin receptor antagonists.", "description": "Number participants who were receiving Angiotensin receptor antagonists treatment.Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "12"}]}]}]}, {"title": "\u03b2-blockers.", "description": "Number participants who were receiving \u03b2-blockers treatment.Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "78"}]}]}]}, {"title": "Antagonists \u0421\u0410 - calcium tubules antagonists.", "description": "Number participants who were receiving Antagonists \u0421\u0410 - calcium tubules antagonists treatment. Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "15"}]}]}]}, {"title": "Antiplatelet agents.", "description": "Number participants who were receiving Antiplatelet agent treatment.Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "39"}]}]}]}, {"title": "Anticoagulants.", "description": "Number participants who were receiving Anticoagulants treatment.Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}]}]}, {"title": "Statins.", "description": "Number participants who were receiving Statins treatment. Basic therapy for hospitalization for planned CABG.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "58"}]}]}]}, {"title": "Echocardiography - 1. Lvd ind. Lvs ind. LAind.", "description": "The data at the time of hospitalization for routine CABG. Indicators of size of the left chambers of the heart. Lvd ind. - left ventricular end-diastolic size index; Lvs ind. - left ventricular end-systolic size index; LA ind. - left atrial index.\n\nThe greater figure (size of the left ventricle - index), worse the prognosis of adverse outcome.The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - size of the left ventricle/ body mass index (kg / m\\^2).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm/ m^2", "classes": [{"title": "Lvd ind.", "categories": [{"measurements": [{"groupId": "BG000", "value": "2.7", "spread": "0.39"}, {"groupId": "BG001", "value": "2.98", "spread": "0.5"}, {"groupId": "BG002", "value": "2.8", "spread": "0.2"}, {"groupId": "BG003", "value": "2.8", "spread": "0.36"}]}]}, {"title": "Lvs ind.", "categories": [{"measurements": [{"groupId": "BG000", "value": "1.8", "spread": "0.42"}, {"groupId": "BG001", "value": "2.1", "spread": "0.5"}, {"groupId": "BG002", "value": "1.9", "spread": "0.4"}, {"groupId": "BG003", "value": "1.9", "spread": "0.44"}]}]}, {"title": "LAind.", "categories": [{"measurements": [{"groupId": "BG000", "value": "2.1", "spread": "0.3"}, {"groupId": "BG001", "value": "2.2", "spread": "0.3"}, {"groupId": "BG002", "value": "2.1", "spread": "0.2"}, {"groupId": "BG003", "value": "2.2", "spread": "0.27"}]}]}]}, {"title": "Echocardiography - 2. LVEDV MOD BP ind. LVESV MOD BP ind.", "description": "The data at the time of hospitalization for routine CABG. Volume indices of left heart chambers.\n\nLVEDV MOD BP ind. - left ventricular end-diastolic volume index. LVESV MOD BP ind. - left ventricular end-systolic volume index.\n\nThe greater figure (size of the left ventricle - index), worse the prognosis of adverse outcome.The index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - size of the left ventricle/ body mass index (kg / m\\^2).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/ m^2", "classes": [{"title": "LVEDV MOD BP ind.", "categories": [{"measurements": [{"groupId": "BG000", "value": "62.4", "spread": "20.7"}, {"groupId": "BG001", "value": "73", "spread": "36.1"}, {"groupId": "BG002", "value": "73.2", "spread": "29.9"}, {"groupId": "BG003", "value": "62.7", "spread": "28.9"}]}]}, {"title": "LVESV MOD BP ind.", "categories": [{"measurements": [{"groupId": "BG000", "value": "23.6", "spread": "14.8"}, {"groupId": "BG001", "value": "32.4", "spread": "27.9"}, {"groupId": "BG002", "value": "31.9", "spread": "22.3"}, {"groupId": "BG003", "value": "27.9", "spread": "21.7"}]}]}]}, {"title": "Echocardiography - 3. LVEF (Simpson) - left ventricular ejection fraction.", "description": "The data at the time of hospitalization for routine CABG. Assessment of the contractility of the left ventricular myocardium (systolic function)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.1", "spread": "7.4"}, {"groupId": "BG001", "value": "56.6", "spread": "10.2"}, {"groupId": "BG002", "value": "59.3", "spread": "11.1"}, {"groupId": "BG003", "value": "59.8", "spread": "9.6"}]}]}]}, {"title": "Echocardiography - 4. Left ventricular diastolic function - 1.", "description": "Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "m/sec", "classes": [{"title": "Peak E of transmitral flow", "categories": [{"measurements": [{"groupId": "BG000", "value": "0.7", "spread": "0.2"}, {"groupId": "BG001", "value": "0.6", "spread": "0.1"}, {"groupId": "BG002", "value": "0.7", "spread": "0.2"}, {"groupId": "BG003", "value": "0.7", "spread": "0.2"}]}]}, {"title": "Peak A of transmitral flow", "categories": [{"measurements": [{"groupId": "BG000", "value": "0.8", "spread": "0.2"}, {"groupId": "BG001", "value": "0.8", "spread": "0.2"}, {"groupId": "BG002", "value": "0.7", "spread": "0.2"}, {"groupId": "BG003", "value": "0.7", "spread": "0.2"}]}]}]}, {"title": "Echocardiography - 5. Left ventricular diastolic function - 2 (E/A).", "description": "The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.9", "spread": "0.4"}, {"groupId": "BG001", "value": "0.9", "spread": "0.5"}, {"groupId": "BG002", "value": "0.9", "spread": "0.5"}, {"groupId": "BG003", "value": "0.9", "spread": "0.47"}]}]}]}, {"title": "Echocardiography - 6. Left ventricular diastolic function - 3 (DT, IVRT).", "description": "Assessment of left ventricular diastolic function. The data at the time of hospitalization for routine CABG. DT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; \\> 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; \\<150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) \\<100 ms - normal; \\> 100 ms - violation of relaxation", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ms.", "classes": [{"title": "DT (Half-time of wave E)", "categories": [{"measurements": [{"groupId": "BG000", "value": "253", "spread": "52.7"}, {"groupId": "BG001", "value": "257.6", "spread": "46.3"}, {"groupId": "BG002", "value": "252.3", "spread": "55.1"}, {"groupId": "BG003", "value": "254.7", "spread": "51.4"}]}]}, {"title": "IVRT (time of isovolumic relaxation of the left ventriclar)", "categories": [{"measurements": [{"groupId": "BG000", "value": "103.4", "spread": "11.1"}, {"groupId": "BG001", "value": "106", "spread": "9.8"}, {"groupId": "BG002", "value": "105.3", "spread": "13.9"}, {"groupId": "BG003", "value": "104.7", "spread": "11.6"}]}]}]}, {"title": "Echocardiography - 7. LVmass/ BSA (g/m^2)", "description": "left ventricular mass (LVmass)/ body surface area (BSA) = left ventricular mass index (g/m\\^2).\n\nMen - normal - 115 g / m\\^2 Women - normal - 95 g / m\\^2", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "119.1", "spread": "29"}, {"groupId": "BG001", "value": "152.8", "spread": "48"}, {"groupId": "BG002", "value": "134.04", "spread": "32"}, {"groupId": "BG003", "value": "135.3", "spread": "36.3"}]}]}]}, {"title": "Echocardiography - 8. RWT - relative wall thickness of the left ventricle.", "description": "Calculated by the formula left ventricular posterior wall thickness + interventricular septal thickness / left ventricular end-diastolic size.\n\nRWT more 0.42 - concentric hypertrophy of the left ventricular myocardium. RWT less or equal 0.42 - eccentric left ventricular myocardial hypertrophy.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.44", "spread": "0.07"}, {"groupId": "BG001", "value": "0.4", "spread": "0.07"}, {"groupId": "BG002", "value": "0.4", "spread": "0.06"}, {"groupId": "BG003", "value": "0.43", "spread": "0.07"}]}]}]}, {"title": "Echocardiography - 9. Mitral regurgitation.", "description": "The data at the time of hospitalization for routine CABG. Evaluation of the degree of Mitral regurgitation by echocardiography data.\n\nAssessment of the degree by the ratio of the area of the regurgitation stream to the area of the left atrium:\n\nGrade 1 (easy) - less than 20% Grade 2 (moderate) - 20-40% Grade 3 (severe) - more than 40% Valve insufficiency is absent in the norm. 2 degree of failure - requires dynamic observation. 3-4 degree of failure requires further examination, the decision of the HeartTeam about the need for surgical correction.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Not", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "30"}]}, {"title": "1 degree Mitral regurgitation.", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "45"}]}, {"title": "2 degree Mitral regurgitation.", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}]}, {"title": "3 degree Mitral regurgitation.", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}]}, {"title": "Echocardiography - 10. Tricuspid regurgitation.", "description": "Criteria tricuspid regurgitation. Grade1-central jet area regurgitation\\<5.0 cm\\^2, Vena contracta is minimal.Grade2-The area of central jet area regurgitation is 5.0-10cm\\^2, Vena contracta is \\<0.7cm. Grade 3-central jet area regurgitation\\>10cm\\^2, Vena contracta\\>0.7cm Additional criterion - retrograde movement of blood in the hepatic vein during systole. Valve insufficiency is absent in the norm. 2degree of failure-requires dynamic observation. 3-4degree of failure requires further examination, the decision of the HeartTeam abCriteria tricuspid insufficiency out the need for surgical correction.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Not", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "66"}]}]}, {"title": "1 degreeTricuspid regurgitation", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "19"}]}]}, {"title": "2 degreeTricuspid regurgitation", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}, {"title": "3 degreeTricuspid regurgitation", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Echocardiography - 11. Aortic regurgitation.", "description": "Evaluation of the degree of Aortic regurgitation by echocardiography data.\n\nUltrasound criteria for the significance of aortic valve insufficiency are determined by the time of the half-decay of the diastolic gradient of the aortic regurgitation flow:\n\n1 stage more than 400 ms; 2 stage 250-400 ms; 3 degree less than 250ms Valve insufficiency is absent in the norm. 2 degree of failure - requires dynamic observation. 3-4 degree of failure requires further examination, the decision of the HeartTeam about the need for surgical correction.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Not", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "22"}, {"groupId": "BG003", "value": "70"}]}]}, {"title": "1 degree Aortic regurgitation.", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "14"}]}]}, {"title": "2 degree Aortic regurgitation.", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "3 degree Aortic regurgitation.", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Echocardiography - 12. Signs of myocardial remodeling.", "description": "The data at the time of hospitalization for routine CABG", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Left ventricular diastolic function/", "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "52"}]}, {"title": "Not", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "33"}]}]}, {"title": "Left ventricular aneurysm.", "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "9"}]}, {"title": "Not", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "76"}]}]}, {"title": "Change in local kinetics.", "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "46"}]}, {"title": "Not", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "39"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Assessment of the Initial Risk of Surgery (EuroScore II).", "description": "EuroScoreII is intended to assess the risk of adverse outcome of coronary artery bypass grafting. Assessment factors: age, sex, serum creatinine, extracardiac artery disease, chronic lung disease, severe neurological disorders, previous cardiac surgery, previous myocardial infarction, left ventricular dysfunction, diabetes mellitus, pulmonary hypertension, IV class of angina severity, active endocarditis, unstable angina, surgery, critical condition of the patient before surgery, type of surgery. The higher the percentage, the higher the risk of surgery.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "Before CABG surgery at baseline.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.68"}, {"groupId": "OG001", "value": "1.07", "spread": "0.47"}, {"groupId": "OG002", "value": "1.02", "spread": "0.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.24", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Length of Hospital Stay. Length of Stay in the Intensive Care Unit.", "description": "The results were obtained from the analysis of primary data.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Primary hospitalization for planned CABG.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.\n\n\u0421ontrol group."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Hospital Stay", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.8", "spread": "11.2"}, {"groupId": "OG001", "value": "32.8", "spread": "13.9"}, {"groupId": "OG002", "value": "38.4", "spread": "15.2"}]}]}, {"title": "Days in the intensive care unite", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "2.2"}, {"groupId": "OG001", "value": "3.1", "spread": "1.7"}, {"groupId": "OG002", "value": "3.3", "spread": "1.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Length of hospital stay.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Length of stay in the intensive care unit.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "The Severity of the Systemic Inflammatory Response in the Postoperative Period (Leukocytosis).", "description": "Assessment of the severity of the systemic inflammatory response during hospital stay after surgery. Assessment of the level of inflammation by the severity of an increase in leukocytes (leukocytosis).\n\nLeukocytosis - an increase in the number of leukocytes per unit volume of blood. The norm of leukocytes in the blood is 5.5-8.810\\^9 /l. For adults, leukocytosis is considered to be an increase in the number of leukocytes in the blood of more than 9.0\\*10\\^9 / l In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "x10^9 cells/L\"", "timeFrame": "The parameters were evaluated initially at baseline in the postoperative period - an interval of 0-6 hours, 12-18 hours, 18-24 hours, 48 hours, 72 hours, 96 hours, 7 days and 14 days.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Leu (leukocytes) / initially", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.3", "spread": "2.2"}, {"groupId": "OG001", "value": "6.5", "spread": "1.5"}, {"groupId": "OG002", "value": "7.3", "spread": "2.04"}]}]}, {"title": "Leu / in the postoperative period - an interval of 0-6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.9", "spread": "6.3"}, {"groupId": "OG001", "value": "14.1", "spread": "1.9"}, {"groupId": "OG002", "value": "16.2", "spread": "5.4"}]}]}, {"title": "Leu / in the postoperative period - an interval of 12-18 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.9", "spread": "3.99"}, {"groupId": "OG001", "value": "14.7", "spread": "5.9"}, {"groupId": "OG002", "value": "13.3", "spread": "3.7"}]}]}, {"title": "Leu / in the postoperative period - an interval of 18-24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.08", "spread": "2.4"}, {"groupId": "OG001", "value": "15.4", "spread": "2.4"}, {"groupId": "OG002", "value": "16.99", "spread": "3.9"}]}]}, {"title": "Leu / in the postoperative period 48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.8", "spread": "5.5"}, {"groupId": "OG001", "value": "14.8", "spread": "2.2"}, {"groupId": "OG002", "value": "13.3", "spread": "3.97"}]}]}, {"title": "Leu / in the postoperative period 72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.3", "spread": "4.1"}, {"groupId": "OG001", "value": "9.4", "spread": "1.6"}, {"groupId": "OG002", "value": "11.4", "spread": "1.9"}]}]}, {"title": "Leu / in the postoperative period 96 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.1", "spread": "2.7"}, {"groupId": "OG001", "value": "8.7", "spread": "2.6"}, {"groupId": "OG002", "value": "10.4", "spread": "1.99"}]}]}, {"title": "Leu / in the postoperative period 7 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.9", "spread": "5.9"}, {"groupId": "OG001", "value": "9.5", "spread": "2.3"}, {"groupId": "OG002", "value": "10.4", "spread": "3.2"}]}]}, {"title": "Leu / in the postoperative period 14 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.8", "spread": "1.6"}, {"groupId": "OG001", "value": "8.8", "spread": "1.7"}, {"groupId": "OG002", "value": "10.4", "spread": "3.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 0-6 hours of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 12-18 hours of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 18-24 hours of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 48 hours of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 72 hours of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 96 hours of the postoperative period/", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 7 days of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Analysis of leukocytes 14 days of the postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Assessment of the Degree of General Inflammatory Response (C-reactive Protein (CRP)),", "description": "Results of dynamic control of laboratory parameters of CRP. C-reactive protein. This fraction of plasma proteins increases in the presence of an inflammatory process in the body. It is synthesized in response to the ingestion of toxins of pathological microorganisms into the bloodstream and neutralizes them by binding them. In addition, it appears when the body's own cells are destroyed in the event of necrosis, tumor disintegration or extensive trauma, inactivating the resulting products. In addition to eliminating toxins, CRP triggers a cascade of immune responses aimed at eliminating pathologically altered structures.\n\nNormally absent (or less than 0.4 mg / l). In the statistical analysis, the grouping of indicators in the indicated intervals was used, in view of the individual characteristics of the course of the postoperative period in each case.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/l", "timeFrame": "Initial data, control point in the interval 4-6 days of the postoperative period, control point in the interval 12-14 days of the postoperative period.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "CRP initially/ mg / l", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.4", "spread": "6.05"}, {"groupId": "OG001", "value": "3.05", "spread": "2"}, {"groupId": "OG002", "value": "5.1", "spread": "5.1"}]}]}, {"title": "CRP control point in the interval 4-6 days of the postoperative period/ mg/l", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.2", "spread": "38"}, {"groupId": "OG001", "value": "85.9", "spread": "51.8"}, {"groupId": "OG002", "value": "121.1", "spread": "76.3"}]}]}, {"title": "CRP control point in the interval 12-14 days of the postoperative period/ mg/l", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.6", "spread": "13.8"}, {"groupId": "OG001", "value": "25.9", "spread": "20.9"}, {"groupId": "OG002", "value": "24.4", "spread": "15.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "CRP initially.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "CRP postoperative 4-6 days.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "CRP postoperative 12-14 days.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.99", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "The Volume of Discharge Through the Drains in the Early Postoperative Period.", "description": "A daily assessment of the discharge by drainage before removal was carried out. It was carried out to assess the possible development of an excessive inflammatory reaction (polyserositis phenomena) in response to the transplantation of autologous bone marrow mononuclear cells.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milliliters", "timeFrame": "Evaluation of these data - for the time spent in the intensive care unit before removing the drains.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "The volume of discharge through the drains on the first day after surgery.", "categories": [{"measurements": [{"groupId": "OG000", "value": "541.2", "spread": "47.9"}, {"groupId": "OG001", "value": "424", "spread": "95.7"}, {"groupId": "OG002", "value": "410", "spread": "59.4"}]}]}, {"title": "The volume of discharge through the drains on the second day after the operation.", "categories": [{"measurements": [{"groupId": "OG000", "value": "189.7", "spread": "27.1"}, {"groupId": "OG001", "value": "152", "spread": "54.2"}, {"groupId": "OG002", "value": "195.4", "spread": "33.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "The volume of discharge through the drains on the first day after surgery.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "The volume of discharge through the drains on the second day after the operation.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "PRIMARY", "title": "Dynamics of Markers of Myocardial Damage (Troponin I, Myoglobin).", "description": "Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mcg / l", "timeFrame": "1 and 3 days of the postoperative period.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Troponin I (postoperative day 1)/mcg / l", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.05", "spread": "18.9"}, {"groupId": "OG001", "value": "5.7", "spread": "5.8"}, {"groupId": "OG002", "value": "2.9", "spread": "2.3"}]}]}, {"title": "Troponin I (postoperative day 3)/mcg / l", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.6", "spread": "31.9"}, {"groupId": "OG001", "value": "3.08", "spread": "3.7"}, {"groupId": "OG002", "value": "1.9", "spread": "1.3"}]}]}, {"title": "Myoglobin postoperative day 1/mcg / l/", "categories": [{"measurements": [{"groupId": "OG000", "value": "522.8", "spread": "711.6"}, {"groupId": "OG001", "value": "385.6", "spread": "221.7"}, {"groupId": "OG002", "value": "757.2", "spread": "1146.8"}]}]}, {"title": "Myoglobin postoperative day 3/mcg / l", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.5", "spread": "1094.8"}, {"groupId": "OG001", "value": "71.4", "spread": "41.4"}, {"groupId": "OG002", "value": "70.4", "spread": "148.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Troponin I postoperative day 1.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Troponin I postoperative day 3.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Myoglobin postoperative day 1.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Myoglobin postoperative day 3.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Dynamics of Markers of Myocardial Damage (Creatine Phosphokinase Fraction MB (CPK-MB)).", "description": "Assessment of the severity of the period of ischemia / reperfusion. And the effect of autologous bone marrow mononuclear cells transplantation on these indicators.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U/l", "timeFrame": "1 and 3 days of the postoperative period.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "CPK-MB postoperative day 1/ U/l", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.3", "spread": "1024"}, {"groupId": "OG001", "value": "63.02", "spread": "79.2"}, {"groupId": "OG002", "value": "78.6", "spread": "136.8"}]}]}, {"title": "CPK-MB postoperative day 3/ U/l", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.4", "spread": "84.7"}, {"groupId": "OG001", "value": "9.5", "spread": "9.3"}, {"groupId": "OG002", "value": "4.6", "spread": "1.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "CPK-MB postoperative day 1.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "CPK-MB postoperative day 3.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Intraoperative Assessment of Homeostasis (Hemoglobin (Hb).", "description": "These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/l", "timeFrame": "Intraoperative data.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Hb intraoperatively before turning off the cardiopulmonary bypass (CPB).", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.05", "spread": "12.2"}, {"groupId": "OG001", "value": "73.4", "spread": "8.08"}, {"groupId": "OG002", "value": "75.8", "spread": "14.5"}]}]}, {"title": "Hb at the end of the operation.", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.3", "spread": "16.09"}, {"groupId": "OG001", "value": "91.5", "spread": "8.6"}, {"groupId": "OG002", "value": "86.7", "spread": "11.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Hb intraoperatively before turning off the cardiopulmonary bypass(CPB).", "nonInferiorityType": "SUPERIORITY", "pValue": "1.0", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Hb at the end of the operation.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Intraoperative Assessment of Homeostasis (Hematocrit (HCT)).", "description": "These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "Intraoperative data.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "HCT intraoperatively before turning off the cardiopulmonary bypass(CPB).", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.4", "spread": "4.2"}, {"groupId": "OG001", "value": "22.2", "spread": "1.9"}, {"groupId": "OG002", "value": "23.2", "spread": "3.9"}]}]}, {"title": "HCT at the end of the operation.", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.3", "spread": "5.2"}, {"groupId": "OG001", "value": "27.8", "spread": "3.2"}, {"groupId": "OG002", "value": "25.7", "spread": "3.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "HCT intraoperatively before turning off the cardiopulmonary bypass (CPB).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "HCT at the end of the operation.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Intraoperative Assessment of Homeostasis (\u041a+).", "description": "These parameters were evaluated at the end of the cardiopulmonary bypass and at the end of the surgery. The interval between indicators is on average from 60 to 120 minutes.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/l", "timeFrame": "Intraoperative data.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "K+ intraoperatively before turning off the cardiopulmonary bypass(CPB).", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.01", "spread": "0.59"}, {"groupId": "OG001", "value": "5.4", "spread": "0.9"}, {"groupId": "OG002", "value": "4.7", "spread": "0.9"}]}]}, {"title": "K+ at the end of the operation.", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "0.4"}, {"groupId": "OG001", "value": "4.5", "spread": "0.6"}, {"groupId": "OG002", "value": "3.9", "spread": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "K+ intraoperatively before turning off the cardiopulmonary bypass (CPB).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "Kruskal-Wallis"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "K+ at the end of the operation.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Cardiopulmonary Bypass Time.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "minutes", "timeFrame": "Intraoperative data.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "135", "spread": "31.6"}, {"groupId": "OG001", "value": "122.8", "spread": "19.7"}, {"groupId": "OG002", "value": "144", "spread": "29.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Time of Aortic Clamping (Anoxia).", "description": "Estimation of the time from the moment the clamp is applied to the aorta (complete clamping of the aorta) to the removal of the clamp from the aorta.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "minutes", "timeFrame": "Intraoperative data.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75.8", "spread": "17.6"}, {"groupId": "OG001", "value": "73.8", "spread": "22.3"}, {"groupId": "OG002", "value": "84", "spread": "18.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "PRIMARY", "title": "Assessment of Complications in the Postoperative Period. Additional Estimation of Safety.", "description": "The presence of complications in the postoperative period (Hydrothorax, Hydropericardium, Cardiac arrhythmias - atrial fibrillation / atrial flutter).", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Postoperative period.", "groups": [{"id": "OG000", "title": "Group 0.", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.\n\n\u0421ontrol group."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Hydrothorax / postoperative period", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Hydropericardium / postoperative period", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Resternotomy / postoperative period", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Atrial fibrillation / postoperative period", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "Atrial flutter / postoperative period", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Hydrothorax / postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "Chi-squared"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Hydropericardium / postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2", "statisticalMethod": "Chi-squared"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Resternotomy / postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "Chi-squared"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Atrial fibrillation / postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.06", "statisticalMethod": "Chi-squared"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Atrial flutter / postoperative period.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.06", "statisticalMethod": "Chi-squared"}]}, {"type": "PRIMARY", "title": "Left Ventricular Ejection Fraction - Echocardiography - Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular the left ventricular ejection fraction, was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The lower the indicator, the worse the prognosis of an unfavorable outcome.", "populationDescription": "all patients included in the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "7-14 days of the postoperative period", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.1", "spread": "1.6"}, {"groupId": "OG001", "value": "56.4", "spread": "2.0"}, {"groupId": "OG002", "value": "55.9", "spread": "2.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "PRIMARY", "title": "Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment - Echocardiography (Size of the Left Ventricle - Index). Additional Estimation of Safety.", "description": "Assessment of myocardial contractility according to echocardiography, in particular the size of the left ventricle - its index, was carried out within 7-14 days of the postoperative period, depending on the clinical condition of the patient, as well as on the maximum information content of this study. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.\n\nThe index is used as an indicator of payment to obtain a more reliable result (taking into account the individual characteristics of each patient).\n\nindex - left ventricular size (mm.)/ body mass index (kg/m\\^2).", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm/m^2", "timeFrame": "7-14 days after surgery", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.\n\n\u0421ontrol group."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Lvd ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "0.08"}, {"groupId": "OG001", "value": "3", "spread": "0.1"}, {"groupId": "OG002", "value": "2.7", "spread": "0.1"}]}]}, {"title": "Lvs ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.07"}, {"groupId": "OG001", "value": "2.1", "spread": "0.09"}, {"groupId": "OG002", "value": "1.9", "spread": "0.09"}]}]}, {"title": "LAind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "2", "spread": "0.06"}, {"groupId": "OG001", "value": "2.2", "spread": "0.07"}, {"groupId": "OG002", "value": "2.1", "spread": "0.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Lvd ind. (Lvd mm./BSA kg / cm) - Evaluation of the left ventricular end-diastolic size index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Lvs ind. (Lvs mm./BSA kg / cm) - Evaluation of the left ventricular end-systolic size index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "LAind. (LA mm./BSA kg / cm) - Left Atrial Size Index Assessment.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "PRIMARY", "title": "Volume of the Left Ventricle - Index - Echocardiography. Assessment of Myocardial Contractility on Days 7-14 After Surgical Treatment. Additional Estimation of Safety.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular volume of the left ventricle - index was carried out within 7-14 days of the postoperative period, depending on the patient's clinical condition, as well as the maximum degree of information content of this study. The greater the figure (volume of the left ventricle - index), the worse the prognosis of adverse outcome.\n\nThe index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - volume of the left ventricle (ml.)/ body mass index (kg / m\\^2).", "populationDescription": "All patients included in the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m^2", "timeFrame": "7-14 days after surgery", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "LVEDV MOD BP ind", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.8", "spread": "4.8"}, {"groupId": "OG001", "value": "70.9", "spread": "6.9"}, {"groupId": "OG002", "value": "63.9", "spread": "5.9"}]}]}, {"title": "LVESV MOD BP ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.5", "spread": "3"}, {"groupId": "OG001", "value": "31.9", "spread": "4.4"}, {"groupId": "OG002", "value": "27.8", "spread": "3.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "LVEDV MOD BP ind. (LVEDV MOD BP ml./BSA kg / cm) - Evaluation of the left ventricular end-diastolic volume index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Evaluation of the left ventricular end-systolic volume index (LVESV MOD BP ind.)", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "PRIMARY", "title": "Restoration of the Heart Rate After the Completion of the Main Stage of the Surgical Intervention. Additional Estimation of Safety.", "description": "The need to perform defibrillation to restore sinus rhythm, at the end of the main stage of surgery.", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Upon completion of the main stage of surgery.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "All-cause Mortality Associated With the Progression of Basic Disease.", "description": "The total number of deaths - in the primary hospitalization and during the observation period of 12 months after surgical treatment - deaths associated with the progression of the initial disease.\n\nThe complication rate for CABG operations is 30\u00b110%. According to n1=kn2; n1 sample size, in the control. In group 0, k=2/3 times more than in group 1 and group 2. The difference between the test and control frequencies is \u03b5=p1-p2. Accordingly, with p1 = 0.2; p2=0.4, \u03b4= 0.1; n1=49.5, n2=33. The result is group 0 - 36, group 1 and 2 - 25+25 = 50. The null hypothesis of complication rate \u03b4.All patients included in the study.", "populationDescription": "All patients included in the study (groups 1 and 2) were compared with the control group (Group 0).In patients included in study during the observation period after the treatment there was no progression of the underlying disease that was fatal.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months after surgery", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.\n\n\u0421ontrol group."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life. Evaluation of the Quality of Life (Minnesota Questionnaire (MHFLQ), Seattle Questionnaire (SAQ), SF-36 Questionnaire). Estimation of Efficiency.", "description": "The SF-36 questionnaire. The indicators of each scale vary between 0 and 100, where 100 represents total health. The results are presented in the form of scores on 8 scales, compiled in such a way that a higher score indicates a higher level of quality of life.MHFLQ - for patients with heart failure.The specified questionnaire consists of 21 questions. To answer each question, a scale of 6 points from the minimum intensity of certain symptoms to the maximum is used. The assessment is based on the sum of points, where the maximum number of points - 105 corresponds to the patient's worst condition. The lowest score 0 points is the best clinical condition of the patient. SAQ consists of 19 questions about the patient's condition, which are divided into the following 5 scales. The quality of life for each of the five scales under consideration is measured in percent, with 0% corresponding to the worst quality of life, and 100% to the best.", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "At baseline and after one year.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Physical Functioning SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.6", "spread": "4.6"}, {"groupId": "OG001", "value": "47.8", "spread": "6.2"}, {"groupId": "OG002", "value": "51.1", "spread": "6.2"}]}]}, {"title": "Physical Functioning SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.9", "spread": "4"}, {"groupId": "OG001", "value": "69.2", "spread": "5.4"}, {"groupId": "OG002", "value": "68.6", "spread": "5.4"}]}]}, {"title": "Role-Physical Functioning SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.2", "spread": "6.2"}, {"groupId": "OG001", "value": "20.8", "spread": "8.4"}, {"groupId": "OG002", "value": "21", "spread": "8.4"}]}]}, {"title": "Role-Physical Functioning SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.7", "spread": "7.4"}, {"groupId": "OG001", "value": "41.7", "spread": "10"}, {"groupId": "OG002", "value": "43.06", "spread": "10"}]}]}, {"title": "Bodily pain SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.9", "spread": "4.9"}, {"groupId": "OG001", "value": "53.3", "spread": "6.7"}, {"groupId": "OG002", "value": "57.8", "spread": "6.7"}]}]}, {"title": "Bodily pain SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "68", "spread": "4.5"}, {"groupId": "OG001", "value": "75.8", "spread": "6.04"}, {"groupId": "OG002", "value": "73.4", "spread": "6.04"}]}]}, {"title": "General Health SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.6", "spread": "2.5"}, {"groupId": "OG001", "value": "50.1", "spread": "3.4"}, {"groupId": "OG002", "value": "45", "spread": "3.4"}]}]}, {"title": "General Health SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4", "spread": "2.4"}, {"groupId": "OG001", "value": "53.2", "spread": "3.3"}, {"groupId": "OG002", "value": "53.5", "spread": "3.3"}]}]}, {"title": "Vitality SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.6", "spread": "3.7"}, {"groupId": "OG001", "value": "54.7", "spread": "4.9"}, {"groupId": "OG002", "value": "53.8", "spread": "4.9"}]}]}, {"title": "Vitality SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.3", "spread": "2.6"}, {"groupId": "OG001", "value": "67.2", "spread": "3.6"}, {"groupId": "OG002", "value": "64.7", "spread": "3.6"}]}]}, {"title": "Social Functioning SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.4", "spread": "4.2"}, {"groupId": "OG001", "value": "65.9", "spread": "5.7"}, {"groupId": "OG002", "value": "66.3", "spread": "5.7"}]}]}, {"title": "Social Functioning SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.8", "spread": "3.9"}, {"groupId": "OG001", "value": "77.08", "spread": "5.2"}, {"groupId": "OG002", "value": "82.6", "spread": "5.2"}]}]}, {"title": "Role- Emotional SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.5", "spread": "7.2"}, {"groupId": "OG001", "value": "40.7", "spread": "9.7"}, {"groupId": "OG002", "value": "38.3", "spread": "9.7"}]}]}, {"title": "Role- Emotional SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.6", "spread": "7.6"}, {"groupId": "OG001", "value": "53.7", "spread": "10.2"}, {"groupId": "OG002", "value": "55.5", "spread": "10.2"}]}]}, {"title": "Mental Health SF-36", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.6", "spread": "3.1"}, {"groupId": "OG001", "value": "64.9", "spread": "4.2"}, {"groupId": "OG002", "value": "67.5", "spread": "4.2"}]}]}, {"title": "Mental Health SF-36 in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "64.5", "spread": "2.9"}, {"groupId": "OG001", "value": "70", "spread": "3.98"}, {"groupId": "OG002", "value": "72.7", "spread": "3.98"}]}]}, {"title": "Minnesota Quality of Life (MHFLQ)", "categories": [{"measurements": [{"groupId": "OG000", "value": "39.8", "spread": "3.6"}, {"groupId": "OG001", "value": "35.1", "spread": "4.9"}, {"groupId": "OG002", "value": "33.3", "spread": "4.9"}]}]}, {"title": "Minnesota Quality of Life (MHFLQ) in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.6", "spread": "2.9"}, {"groupId": "OG001", "value": "22.7", "spread": "3.9"}, {"groupId": "OG002", "value": "22.1", "spread": "3.9"}]}]}, {"title": "Seattle QuestionnairePhysical limitation", "categories": [{"measurements": [{"groupId": "OG000", "value": "39.6", "spread": "3.5"}, {"groupId": "OG001", "value": "42.6", "spread": "5.4"}, {"groupId": "OG002", "value": "40", "spread": "5.2"}]}]}, {"title": "SeattleQuestionnairePhysical limitation / in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.5", "spread": "2.9"}, {"groupId": "OG001", "value": "60.8", "spread": "4.4"}, {"groupId": "OG002", "value": "58.6", "spread": "4.3"}]}]}, {"title": "SeattleQuestionnaireAngina stability", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.5", "spread": "6.3"}, {"groupId": "OG001", "value": "40.4", "spread": "9.7"}, {"groupId": "OG002", "value": "61", "spread": "9.4"}]}]}, {"title": "SeattleQuestionnaireAngina stability / in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "87", "spread": "7.1"}, {"groupId": "OG001", "value": "91.9", "spread": "10.9"}, {"groupId": "OG002", "value": "98.2", "spread": "10.6"}]}]}, {"title": "SeattleQuestionnaireAngina frequency", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.7", "spread": "5.7"}, {"groupId": "OG001", "value": "48.5", "spread": "8.8"}, {"groupId": "OG002", "value": "46.07", "spread": "8.5"}]}]}, {"title": "SeattleQuestionnaiAngina frequency / in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.3", "spread": "4.2"}, {"groupId": "OG001", "value": "90.8", "spread": "6.6"}, {"groupId": "OG002", "value": "86.4", "spread": "6.3"}]}]}, {"title": "SeattleQuestionnaireTreatment satisfaction", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.9", "spread": "3.7"}, {"groupId": "OG001", "value": "72.1", "spread": "5.8"}, {"groupId": "OG002", "value": "69.6", "spread": "5.6"}]}]}, {"title": "SeattleQuestionnaireTreatmentSatisfaction/ in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.2", "spread": "3.2"}, {"groupId": "OG001", "value": "81.3", "spread": "4.9"}, {"groupId": "OG002", "value": "80.4", "spread": "4.8"}]}]}, {"title": "SeattleQuestionnaire Disease perception", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.4", "spread": "4.3"}, {"groupId": "OG001", "value": "36.5", "spread": "6.7"}, {"groupId": "OG002", "value": "37.9", "spread": "6.5"}]}]}, {"title": "SeattleQuestionnaire Disease perception/ in year", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.7", "spread": "24.4"}, {"groupId": "OG001", "value": "64.2", "spread": "20.8"}, {"groupId": "OG002", "value": "64.3", "spread": "20.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Physical Functioning SF-36. Comparison of patients of group 1 and group 2 with the control group - group 0.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Role-Physical Functioning SF-36", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Bodily pain SF-36", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "General Health SF-36.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Vitality SF-36.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Social Functioning SF-36.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Role- Emotional SF-36.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Mental Health SF-36.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.96", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Minnesota Quality of Life (MHFLQ).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Seattle QuestionnairePhysical limitation.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "SeattleQuestionnaireAngina stability.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "SeattleQuestionnaireAngina frequency.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "SeattleQuestionnaireTreatment satisfaction.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "SeattleQuestionnaire Disease perception.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Assessment of the Functional Class of Exertional Angina at 12 Months After Surgical Treatment.", "description": "1. functional class - The usual load does not cause changes in the state of health. Painful attacks occur against the background of excessive loads - after climbing several flights of stairs, while walking fast.\n2. functional class - Pain attacks when walking more than 500 meters, when climbing stairs more than one floor.\n3. functional class - The patient does not tolerate minimal physical activity. An attack occurs when walking a distance of 50-100 meters. Climbing stairs is difficult.\n4. functional class - Activity is significantly limited. Angina pectoris manifests itself when performing minimal actions, including at rest.", "populationDescription": "Data analysis of all patients underwent follow-up examination 12 months after surgery.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "up to 12 months", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "1 functional class of angina pectoris1 year after", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "2 functional class of angina pectoris1 year after", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "3 functional class of angina pectoris1 year after", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "4 functional class of angina pectoris1 year after", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.001", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Dynamics of the Functional Class of Heart Failure (NYHA). Estimation of Efficiency.", "description": "1. functional class - There is no limitation of a person's physical activity, shortness of breath manifests itself when going above the third floor.\n2. functional class - slight limitation of activity, palpitations, shortness of breath, fatigue occur during normal physical activity and more.\n3. functional class - Symptoms occur with the smallest physical activity, resulting in a significant decrease in activity. At rest, clinical manifestations are not observed.\n\nThe smaller the functional class, the better the quality of human life.", "populationDescription": "In one case, a patient of Groups 1 through 12 months after the treatment, marked progression of the functional class of heart failure. It should be noted that this patient did not adhere to the recommendations on lifestyle and drug therapy in the postoperative period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Assessment of the dynamics at 12 months after treatment.", "groups": [{"id": "OG000", "title": "Group 0", "description": "Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "1 functional class heart failure (NYHA).", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "2 functional class heart failure (NYHA).", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "15"}]}]}, {"title": "3 functional class heart failure (NYHA).", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.13", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Evaluation of the Left Ventricular Ejection Fraction 12 Months After Treatment.", "description": "According to echocardiography.", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "12 months after treatment.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61.4", "spread": "1.5"}, {"groupId": "OG001", "value": "58.1", "spread": "1.8"}, {"groupId": "OG002", "value": "58.4", "spread": "1.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.35", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Estimation of the Index of Linear Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular the size of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular size - index), the worse the prognosis of an unfavorable outcome.\n\nThe index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - size of the left ventricle (mm.)/ body mass index (kg/m\\^2).", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm/m^2", "timeFrame": "12 months after the treatment.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Lvd ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "0.07"}, {"groupId": "OG001", "value": "2.9", "spread": "0.08"}, {"groupId": "OG002", "value": "2.8", "spread": "0.09"}]}]}, {"title": "Lvs ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.9", "spread": "0.06"}, {"groupId": "OG001", "value": "2.07", "spread": "0.08"}, {"groupId": "OG002", "value": "1.8", "spread": "0.08"}]}]}, {"title": "LAind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "0.05"}, {"groupId": "OG001", "value": "2.3", "spread": "0.07"}, {"groupId": "OG002", "value": "2.2", "spread": "0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Lvd ind. (Lvd mm./BSA) - left ventricular end-diastolic size index. All patients included in the study.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Lvs ind. (Lvs mm./BSA kg / cm) - left ventricular end-systolic size index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "LAind. (LA mm./BSA kg / cm) - left atrial index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Estimation of the Index of Volumetric Parameters of the Left Ventricle 12 Months After the Treatment. Estimation of Efficiency.", "description": "Evaluation of myocardial contractility according to echocardiography, in particular the volume of the left ventricle - the index was carried out 12 months after CABG. The higher the indicator (left ventricular volume - index), the worse the prognosis of an unfavorable outcome.\n\nThe index is used as an indicator of the payment to obtain a more reliable result (taking into account individual characteristics of each patient).\n\nindex - volume of the left ventricle (mm.)/ body mass index (kg/m\\^2).", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m^2", "timeFrame": "12 Months After the Treatment", "groups": [{"id": "OG000", "title": "Group 0", "description": "Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "LVEDV MOD BP ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.3", "spread": "4.4"}, {"groupId": "OG001", "value": "70.4", "spread": "6.2"}, {"groupId": "OG002", "value": "66.9", "spread": "5.5"}]}]}, {"title": "LVESV MOD BP ind.", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.2", "spread": "2.6"}, {"groupId": "OG001", "value": "31.5", "spread": "3.9"}, {"groupId": "OG002", "value": "25.6", "spread": "3.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "LVEDV MOD BP ind. (LVEDV MOD BP ml./BSA kg / cm) - left ventricular end-diastolic volume index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "LVESV MOD BP ind. (LVESV MOD BP ml./BSA kg / cm) - left ventricular end-systolic volume index.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Assessment of Left Ventricular Diastolic Function - Peak E of Transmitral Flow and Peak \u0410 of Transmitral Flow 12 Months After Treatment.", "description": "Evaluation of left ventricular diastolic function (echocardiography). The peak velocity E reflects the pressure gradient between the LA and LV in early diastole, and it is affected by preload and disturbance LV relaxation The speed of peak A, which forms at the end diastole, influences LV compliance and contractility left atrium.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters/sec.", "timeFrame": "12 months after treatment.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Peak E of transmitral flow", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.04"}, {"groupId": "OG001", "value": "0.7", "spread": "0.05"}, {"groupId": "OG002", "value": "0.8", "spread": "0.05"}]}]}, {"title": "Peak \u0410 of transmitral flow", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.09"}, {"groupId": "OG001", "value": "07", "spread": "0.1"}, {"groupId": "OG002", "value": "0.8", "spread": "0.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Peak E of transmitral flow", "nonInferiorityType": "SUPERIORITY", "pValue": "0.35", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Peak A of transmitral flow.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Assessment of Left Ventricular Diastolic Function E/A - 12 Months After Treatment.", "description": "The ratio of the transmitral flow, wave E (ejection wave / left ventricular contraction) to wave A (ejection wave / left atrial contraction). The norm is 0.75-1.5 Less than 0.75 violation of relaxation, more than 1.5 restrictive type of diastolic dysfunction.", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "12 months after treatment", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1", "spread": "0.1"}, {"groupId": "OG001", "value": "1.2", "spread": "0.1"}, {"groupId": "OG002", "value": "1.2", "spread": "0.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Peak E of transmitral flow/ Peak A of transmitral flow (E/A).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Assessment of Left Ventricular Diastolic Function - DT and IVRT 12 Months After Treatment.", "description": "Echocardiographic data ( DT (Half-time of wave E), time of isovolumic relaxation of the left ventricle (IVRT).\n\nDT (Half-time of wave E). The DT time index reflects the relaxation process LV, LV diastolic pressure after mitral valve opening, and LV compliance. 150-200 ms - normal; \\> 200 ms - violation of relaxation; 150-200 ms - pseudonormal type of left ventricular filling; \\<150 ms - restrictive type of diastolic dysfunction IVRT (time of isovolumic relaxation of the left ventricl.) \\<100 ms - normal; \\> 100 ms - violation of relaxation", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ms", "timeFrame": "12 Months After Treatment.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "DT (Half-time of wave E).", "categories": [{"measurements": [{"groupId": "OG000", "value": "250.4", "spread": "15.2"}, {"groupId": "OG001", "value": "252.6", "spread": "20.08"}, {"groupId": "OG002", "value": "256.6", "spread": "18.3"}]}]}, {"title": "time of isovolumic relaxation of the left ventricle (IVRT).", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.9", "spread": "4.1"}, {"groupId": "OG001", "value": "102.4", "spread": "5.5"}, {"groupId": "OG002", "value": "99.6", "spread": "4.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "DT (Half-time of wave E).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9", "statisticalMethod": "RepeatedMeasures ANOVA"}, {"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "time of isovolumic relaxation of the left ventricle", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9", "statisticalMethod": "RepeatedMeasures ANOVA"}]}, {"type": "SECONDARY", "title": "Distance Traveled in the 6-minute Walk Test. Test Results With 6 Minute Walk", "description": "The dynamic of the number of meters walked according to the 6-minutes walk test (6MWD) in the observation groups.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "initially and after 12 months", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Original number of meters.", "categories": [{"measurements": [{"groupId": "OG000", "value": "315.06", "spread": "17.6"}, {"groupId": "OG001", "value": "319.8", "spread": "24.5"}, {"groupId": "OG002", "value": "329.9", "spread": "25.3"}]}]}, {"title": "Number of meters in 12 months.", "categories": [{"measurements": [{"groupId": "OG000", "value": "433.54", "spread": "20.6"}, {"groupId": "OG001", "value": "524.4", "spread": "28.7"}, {"groupId": "OG002", "value": "452.7", "spread": "29.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0367", "statisticalMethod": "Kruskal-Wallis"}]}, {"type": "SECONDARY", "title": "The Number of Functioning Grafts 12 Months After CABG. Patency of Grafts Within a Specified Time of Treatment (Angiography).", "description": "According to the angiographic study.", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of grafts", "timeFrame": "up to 12 months", "groups": [{"id": "OG000", "title": "Group 0", "description": "Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Initial number of grafts", "categories": [{"measurements": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "75"}]}]}, {"title": "Number of functioning grafts at 12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "76"}, {"groupId": "OG002", "value": "73"}]}]}, {"title": "Number of non-functioning grafts after 12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Assessment of the functioning of grafts. Patency of grafts within a specified time of treatment (angiography).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.04", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Analysis of the Effect of Left Ventricular Diastolic Dysfunction on the Patency of the Grafts.", "description": "Echocardiographic data.", "populationDescription": "All patients included in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "up to 12 months", "groups": [{"id": "OG000", "title": "Intramyocardial Administration 0.9 % NaCl (Sodium Chloride) - Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Intramyocardial Administration Autologous Bone Marrow Stem Cells - Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Intramyocardial and Intracoronary Administration Autologous Bone Marrow Stem Cells - Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Number of patients with non-functioning grafts", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Patients with non-functioning grafts in the presence of LV diastolic dysfunction after 12 months.", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.05", "statisticalMethod": "Chi-squared"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "The Volume of Cellular Material (Cytosis).", "description": "Dependence and Duration of Positive Clinical Effect on the Amount of Injected Cell Material (cytosis).", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "*10^8cells/l", "timeFrame": "Initial data at the time of collection of bone marrow cells.", "groups": [{"id": "OG000", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial ( 0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow mononuclear cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.3", "spread": "8.9"}, {"groupId": "OG001", "value": "20.3", "spread": "8.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.05", "statisticalMethod": "Discriminant Analysis"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "The Amount of Cell Material (Percentage).", "description": "Dependence and duration of positive clinical effect on the amount of injected cell material (Mononuclear fraction %, CD34+ %, CD133+ %).\n\nAssessment - mononuclear fraction, CD 34 +, CD 133+ according to flow cytometry data.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "Initial data at the time of collection of bone marrow cells.", "groups": [{"id": "OG000", "title": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Mononuclear fraction/ %", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.04", "spread": "2.9"}, {"groupId": "OG001", "value": "20.0", "spread": "2.7"}]}]}, {"title": "CD34+/ %", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.16", "spread": "0.22"}, {"groupId": "OG001", "value": "1.18", "spread": "0.34"}]}]}, {"title": "CD133+/ %", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "0.08"}, {"groupId": "OG001", "value": "0.38", "spread": "1.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Mononuclear fraction %", "nonInferiorityType": "SUPERIORITY", "pValue": "0.05", "statisticalMethod": "Discriminant Analysis", "statisticalComment": "Data were analyzed by 1, 2, and 3 sections according to the study design."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "CD34+ %", "nonInferiorityType": "SUPERIORITY", "pValue": "0.057", "statisticalMethod": "Discriminant Analysis", "statisticalComment": "Data were analyzed by 1, 2, and 3 sections according to the study design."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "CD133+ %", "nonInferiorityType": "SUPERIORITY", "pValue": "0.05", "statisticalMethod": "Discriminant Analysis"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Smoking as a Factor That Negatively Affects the Results of the Test With a 6-minute Walk in Dynamics.", "description": "The distance covered (in meters) was compared with the proper value depending on age (years), height (cm), weight (kg), body mass index (BMI). The due values (6MWD (i)) were calculated using the following formulas: For men: 6\u041cWD (i) = 7.57 \u00d7 height - 5.02 \u00d7 age - 1.76 \u00d7 weight - 309 or 6MWD (i) = 1140 - 5.61 \u00d7 BMI - 6.94 \u00d7 age. For women:\n\n6\u041cWD (i) = 2.11 \u00d7 height - 2.29 \u00d7 weight - 5.78 \u00d7 age + 667 Or 6\u041cWD (i) = 1017 - 6.24 \u00d7 BMI - 5.83 \u00d7 age. This difference at baseline is reported as distance walked for smokers minus non-smokers.", "populationDescription": "The data of all patients initially included in the study were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "12 months after treatment.", "groups": [{"id": "OG000", "title": "Group 0", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG001", "title": "Group 1", "description": "\u0421oronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD."}, {"id": "OG002", "title": "Group 2", "description": "\u0421oronary artery bypass grafting with intramyocardial ( 0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow mononuclear cells."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "diference between smokers and non-smoking participants at baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "23"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "230.04", "spread": "28.7"}, {"groupId": "OG001", "value": "215.3", "spread": "31.4"}, {"groupId": "OG002", "value": "224.8", "spread": "27.1"}]}]}, {"title": "diference between baseline and1 year after surgery", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "87.9", "spread": "4.9"}, {"groupId": "OG001", "value": "8.5", "spread": "2.7"}, {"groupId": "OG002", "value": "62.1", "spread": "4.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "Factor analysis - determining the influence of a factor, in this case, smoking, on the deficit in the number of meters passed according to the test with a 6-minute walk.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.046", "statisticalMethod": "Factor analysis"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "12 months after treatment", "eventGroups": [{"id": "EG000", "title": "Group 0", "description": "Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.", "deathsNumAffected": 0, "deathsNumAtRisk": 37, "seriousNumAffected": 0, "seriousNumAtRisk": 37, "otherNumAffected": 0, "otherNumAtRisk": 37}, {"id": "EG001", "title": "Group 1", "description": "Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow stem cells 0.2 ml - 10 injection in the zone of blood supply LAD.", "deathsNumAffected": 0, "deathsNumAtRisk": 25, "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 0, "otherNumAtRisk": 25}, {"id": "EG002", "title": "Group 2", "description": "Coronary artery bypass grafting with intramyocardial (0.2 ml - 10 injection in the zone of blood supply LAD) and intracoronary administration of autologous bone marrow stem cells.", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 0, "otherNumAtRisk": 23}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "No limitations identified."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Vladimir V Komok, Ph.D", "organization": "First Pavlov State Medical University of St. Petersburg", "email": "vladimir_komok@mail.ru", "phone": "8-904-632-19-00"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000003327", "term": "Coronary Disease"}, {"id": "D000003324", "term": "Coronary Artery Disease"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000001161", "term": "Arteriosclerosis"}, {"id": "D000001157", "term": "Arterial Occlusive Diseases"}], "browseLeaves": [{"id": "M6546", "name": "Coronary Artery Disease", "asFound": "Ischemic Heart Disease", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M19506", "name": "Myocardial Ischemia", "asFound": "Ischemic Heart Disease", "relevance": "HIGH"}, {"id": "M6549", "name": "Coronary Disease", "asFound": "Coronary Heart Disease", "relevance": "HIGH"}, {"id": "M18099", "name": "Reperfusion Injury", "relevance": "LOW"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Heart Failure, Diastolic", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M4469", "name": "Arteriosclerosis", "relevance": "LOW"}, {"id": "M4465", "name": "Arterial Occlusive Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": true}